{"id":8840,"date":"2025-06-26T06:16:52","date_gmt":"2025-06-26T11:16:52","guid":{"rendered":"https:\/\/nanostherapeutics.com\/?p=8840"},"modified":"2025-07-13T15:08:42","modified_gmt":"2025-07-13T20:08:42","slug":"nanoscope-therapeutics-propels-patient-centered-innovation-in-inherited-retinal-diseases-with-new-visionary-advisory-committee","status":"publish","type":"post","link":"https:\/\/nanostherapeutics.com\/es\/2025\/06\/26\/nanoscope-therapeutics-propels-patient-centered-innovation-in-inherited-retinal-diseases-with-new-visionary-advisory-committee\/","title":{"rendered":"Nanoscope Therapeutics impulsa la innovaci\u00f3n centrada en el paciente en enfermedades retinianas hereditarias con un nuevo comit\u00e9 asesor visionario."},"content":{"rendered":"
\n\t\t\t\t\t\t
\r\n\t\t\t\t\t\t\t\t
\r\n\t\t\t\t\r\n\t\t\t\t\t\t\t\t
\r\n\r\n\t\t\t\t\r\n\t\t\t\t
\r\n\t\t\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

\u00a0<\/h3><\/div>

DALLAS<\/span><\/span>,\u00a026 de junio de 2025 <\/span><\/span>\u2014\u00a0Nanoscopio Therapeutics Inc.<\/a>, una empresa de biotecnolog\u00eda comprometida con el desarrollo y la comercializaci\u00f3n de nuevas terapias gen\u00e9ticas independientes para pacientes que sufren una p\u00e9rdida grave de la visi\u00f3n debido a enfermedades degenerativas de la retina, anunci\u00f3 hoy la formaci\u00f3n de su\u00a0Comit\u00e9 Asesor Visionario (VAC)<\/a>\u00a0– a group of renowned experts in retina treatment and commercialization.<\/p>

The VAC will serve as a strategic and mission-aligned team that informs Nanoscope’s scientific, clinical, and community-facing efforts.\u00a0Su misi\u00f3n: mejorar la atenci\u00f3n a los pacientes, fomentar una colaboraci\u00f3n aut\u00e9ntica con los m\u00e9dicos y ayudar a trazar el camino para ofrecer una terapia transformadora, en primer lugar, a las personas que viven con retinosis pigmentaria (RP) y enfermedad de Stargardt (SD).<\/i><\/b><\/p>

“This is more than just a committee \u2014 it represents a clear declaration of our unwavering commitment to the patients we serve and the mission in which we believe,” said\u00a0Sulagna Bhattacharya<\/span>, co-founder and CEO of Nanoscope Therapeutics. “At Nanoscope we’re building the future of retinal care with our eyes wide open, guided by those who truly understand the lives of the patients we are committed to helping.”<\/p>

MCO-010 is the most advanced clinical-stage optogenetic therapy in development for RP. Using Nanoscope’s proprietary Multi-Characteristic Opsin (MCO), MCO-010 is the first optogenetic investigational therapy to demonstrate potential vision restoration in patients with severe vision loss in clinical trials.<\/p>

“What sets MCO-010 apart is not only its scientific advances, but its real-world accessibility,” added Bhattacharya. “It’s designed to be delivered as a single, in-office injection\u2014without the need for genetic testing, surgery, or ongoing maintenance.”<\/p>

El\u00a0El Comit\u00e9 de Vigilancia Vecinal estar\u00e1 presidido por SriniVas Sadda, MD.<\/b>., la A.\u00a0Ray Irvine, Jr.<\/span>, Doctor en Medicina, C\u00e1tedra de Oftalmolog\u00eda Cl\u00ednica y Profesor en la\u00a0Universidad de California, Los \u00c1ngeles<\/span>\u00a0Facultad de Medicina David Geffen e Instituto Oftalmol\u00f3gico Doheny.<\/p>

“As retina specialists, we face a desperate need to change the conversation about blindness with our patients \u2014 from one of inevitability to one of possibility,” said Dr. Sadda. “I’m honored to be part of a team that believes the status quo is not set in stone, and that restoration of vision is not a dream \u2014 it’s a goal within reach.”<\/p>

Adem\u00e1s del Dr. Sadda, entre los miembros del VAC se encuentran:<\/p>